Top

International Journal of Mental Health and Addiction

Published in:

01-04-2006

The Management of Anxiety and Depressive Disorders: A Review

Author: Jude U. Ohaeri

Published in: International Journal of Mental Health and Addiction | Issue 2/2006

Abstract

While anxiety and mild-moderate depression (the so-called neuroses) are the commonest mental disorders, they receive scant attention. They should be considered together, because they commonly occur together, are typically chronic, and respond to the same treatment. This review challenges traditional notions about the neuroses, by examining the reasons for their co-morbidity, the effectiveness of SSRIs in anxiety, and the biological basis of anxiety. From neuro-endocrine, psycho-immunology, genetic and clinical studies, anxiety and depression could denote manifestations of an underlying cause. Anxiety results from a dysregulation of homeostasis in the serotonin and noradrenergic systems, which SSRIs stabilize. Treatment guidelines recommend that SSRIs and SNRI should be first-line in the treatment of anxiety disorders, in combination with psychotherapy, with benzodiazepines used on short-term basis. Remission should be the goal of treatment. Outcome should include clinical, functional and disability assessments, graded in terms of response, remission and recovery. Perhaps the SSRIs and SNRI should be recognized as anti-neurotic. Mental disorders probably exist in a biological system with serotonin at the root of the neuroses, while dopamine sub-stands the psychoses.

Alonso, J., Angermeyer, M. C., Bernert, S., Bruffaerts, R., Brugha, T. S., Bryson, H., et al. (2004). Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica (Suppl.420), 21–27.

Allgulander, C., Bandelow, B., Hollander, E., Montgomery, S. A., Nutt, D. J., Okasha, A., et al. (2003). WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectrum, 8 (8 Suppl. 1), 53–61.

Bakish, D. (1999). The patient with co-morbid depression and anxiety: the unmet need. Journal of Clinical Psychiatry, 60(Suppl. 6), 20–24.PubMed

Baldwin, D. S. (2000). Clinical experience with paroxetine in social anxiety disorder. International Clinical Psychopharmacology, 15(Suppl 1), S19–S24.PubMed

Coplan, J. D., & Lydiard, R. B. (1998). Brain circuits in panic disorder. Biological Psychiatry, 44, 1264–1276.PubMedCrossRef

Coplan, J. D., Papp, L. A., Martinez, J., Pine, D., Rosenblum, L. A., Cooper, T., et al. (1995). Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. American Journal of Psychiatry, 152, 619–622.PubMed

Coplan, J. D., Papp, L. A., Pine, D., Martinez, M. A., Cooper, T., Rosenblum, L. A., et al. (1997). Clinical improvement with fluoxetine therapy and nor-adrenergic function in patients with panic disorder. Archives of General Psychiatry, 54, 643–648.PubMed

Coplan, J. D., Tamir, H., Calaprice, D., De Jesus, M., dela Nuez, M., Pine, D., et al. (1999). Plasma anti-serotonin and serotonin anti-idiotypic antibodies are elevated in panic disorder. Neuropsychopharmacology, 20, 386–391.PubMedCrossRef

Coryell, W. (1988). Panic disorder and mortality. Psychiatric Clinics of North America, 11, 433–440.PubMed

Coryell, W., Endicott, J., & Winokur, G. (1992). Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology. American Journal of Psychiatry, 149, 100–107.PubMed

Cox, B. J., Direnfeld, D. M., Swinson, R. P., & Norton, G. R. (1994). Suicidal Ideation and suicide attempts in panic disorder and social phobia. American Journal of Psychiatry, 151, 882–887.PubMed

Davidson, J. R., Bose, A., Korotzer, A., & Zheng, H. (2004). Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depression and Anxiety, 19, 234–240.PubMedCrossRef

De Graaf, R., Bijl, R. V., Smit, F., Vollenbergh, W. A., & Spijker, J. (2002). Risk factors for 12-month co-morbidity of mood, anxiety, and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study. American Journal of Psychiatry, 159, 620–629.PubMedCrossRef

De Jonghe, F., Kool, S., van Aalst, G., Dekker, J., & Peen, J. (2001). Combining psychotherapy and antidepressants in the treatment of depression. Journal of Affective Disorders, 64, 217–229.PubMedCrossRef

Dupont, R. I., Rice, D. P., Shiraki, S., & Rowland, C. R. (1995). Economic costs of obsessive compulsive disorder. Medicine Interface, 8, 102–109.

Duran, B., Sanders, M., Skipper, B., Waitzkin, H., Malcoe, L. H., Paine, S., & Yager, J. (2004). Prevalence and correlates of mental disorders among Native American women in primary care. American Journal of Public Health, 94, 71–77.PubMedCrossRef

Fava, M., Rankin, M. A., Wright, E. C., Alpert, J. E., Nierenberg, A. A., Pava, J., & Rosenbaum, J. F. (2000). Anxiety disorders in major depression. Comprehensive Psychiatry, 41, 97–102.PubMedCrossRef

Feighner, J. P. (1999). Overview of antidepressants currently used to treat anxiety disorders. Journal of Clinical Psychiatry, 60(Suppl. 22), 18–22.PubMed

Frances, A., Manning, D., Marin, D., Kocsis, J., McKinney, K., Hall, W., & Kline, M. (1992). Relationship of anxiety and depression. Psychopharmacology, 106 (Suppl.), 82–86.CrossRef

Furukawa, T. A., McGuire, H., & Barbui, C. (2003). Low dosage tricyclic antidepressants for depression. Cochrane Database Systematic Review, (3), CD 003197.

Furukawa, T. A., Streiner, D. L., & Young, L. T. (2001). Is antidepressant–benzodiazepine combination therapy clinically more useful? A meta-analytical study. Journal of Affective Disorders, 65, 173–177.PubMedCrossRef

Goodwin, R. D., Fergusson, D. M., & Horwood, L. J. (2004). Panic attacks and psychoticism. American Journal of Psychiatry, 161, 88–92.PubMedCrossRef

Goodwin, R. D., & Gotlib, I. H. (2004). Panic attacks and psychopathology among youths. Acta Psychiatrica Scandinavica, 109, 216–221.PubMedCrossRef

Gorman, J. M., & Coplan, J. D. (1996). Comorbidity of depression and panic disorder. Journal of Clinical Psychiatry, 57(Suppl. 10), 34–41.PubMed

Harter, M. C., Conway, K. P., & Merikangas, K. R. (2003). Association between anxiety disorders and physical illness. European Archives of Psychiatry and Clinical Neurosciences, 253, 313–320.CrossRef

Hirschfeld, R. M. (2001). The co-morbidity of major depression and anxiety disorders: recognition and management in primary care. Primary Care Companion of Journal of Clinical Psychiatry, 3, 244–254.

Humphris, G. M., Rogers, S., McNally, D., Lee-Jones, C., Brown, J., & Vaughan, D. (2003). Fear of recurrence and possible cases of anxiety and depression in oro-facial cancer patients. International Journal of Oral Maxillofacial Surgery, 32, 486–491.CrossRef

Johnson, J., Weissman, M. M., & Klerman, G. L. (1990). Panic disorder, co-morbidity and suicide attempts. Archives of General Psychiatry, 47, 805–808.PubMed

Jorm, A. F., Korten, A. E., Christensen, H., Jacomb, P. A, Rodgers, B., & Parslow, R. A. (2003). Association of obesity with anxiety, depression and emotional well-being: a community survey. Australia and New Zealand Journal of Public Health, 27, 434–440.CrossRef

Kapczinnski, F., Lima, M. S., Souza, J. S., & Schimitt, R. (2003). Antidepressants for generalized anxiety disorder. Cochrane Database Systematic Review, (2), CD 003592.

Kara, S., Yazici, K. M., Gulec, C., & Unsal, I. (2000) Mixed anxiety-depressive disorder and major depressive disorder: comparison of the severity of illness and biologic variables. Psychiatry Research, 94, 59–66.PubMedCrossRef

Karlidag, R., Unal, S., Evereklioglu, C., Sipahi, B., Er, H., & Yologlu, E. (2003). Stressful life events, anxiety, depression and coping mechanisms in patients with Behcet's disease. Journal of European Academy of Dermatology and Venerology, 17, 670–675.CrossRef

Kawakami, N., Shimizu, H., Haratani, T., Iwata, N., & Kitamura, T. (2004). Lifetime and 6-month prevalence of DSM-111-R psychiatric disorders in an urban community in Japan. Psychiatry Research, 121, 293–301.PubMedCrossRef

Kendler, K. S. (2001). Twin studies of psychiatric illness: an update. Archives of General Psychiatry, 58, 1005–1014.PubMedCrossRef

Kendler, K. S., Neale, M. C., Kessler, R. C., Heath, A. C., & Eaves, L. J. (1992). Major depression and generalized anxiety disorder: same genes (partly) different environments? Archives of General Psychiatry, 49, 716–722.PubMed

Kent, J. M., Coplan, J. D., & Gorman, J. M. (1998). Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biological Psychiatry, 44, 812–824.PubMedCrossRef

Kiloh, L. G., Andrews, G., Neilson, M., & Bianchi, G. N. (1972). The relationship of the syndromes called endogenous and neurotic depression. British Journal of Psychiatry, 121, 183–196.PubMedCrossRef

Kiloh, L. G., & Garside, R. F. (1963). The independence of neurotic depression and endogenous depression. British Journal of Psychiatry, 109, 451–463.PubMedCrossRef

Kjernisted, K. D., & Bleau, P. (2004). Long-term goals in the management of acute and chronic anxiety disorders. Canadian Journal of Psychiatry, 49(Suppl. 1), 51s–63s.

Lalonde, P. (2003). Evaluating antipsychotic medications: predictors of clinical effectiveness. Canadian Journal of Psychiatry, 48(Suppl. 1), 3s–12s.

Lam, R. W., & Kennedy, S. H. (2004). Evidence-based strategies for achieving and sustaining full remission in depression: focus on meta-analysis. Canadian Journal of Psychiatry, 49(Suppl. 1), 17s–26s.

Lecrubier, Y., & Judge, R. (1997). Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative paroxetine panic study investigators. Acta Psychiatrica Scandinavica, 95, 153–160.PubMedCrossRef

Leon, A. C., Shear, M. K., Portera, L., & Klerman, G. L. (1992). Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Social Psychiatry and Psychiatric Epidemiology, 27, 78–82.PubMedCrossRef

Liebowitz, M. R., Stein, M. B., Tancer, M., Carpenter, D., Oakes, R., & Pitts, C. D. (2002). A randomized, double-blind, fixed dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry, 63, 66–74.PubMed

Lochner, C., Mogotsi, M., du Toit, P. L., Kaminer, D., Niehaus, D. J., & Stein, D. J. (2003). Quality of life in anxiety disorders: a comparison of obsessive–compulsive disorder, social anxiety disorder and panic disorder. Psychopathology, 36, 255–262.PubMedCrossRef

Lydiard, R. B., & Bobes, J. (2000). Therapeutic advances: paroxetine for the treatment of social anxiety disorder. Depression and Anxiety, 11, 99–104.PubMedCrossRef

Malhi, G. S., Parker, G. B., Gladstone, G., Wilhelm, K., & Mitchell, P. B. (2002). Recognizing the anxious face of depression. Journal of Nervous and Mental Disorders, 190, 366–373.CrossRef

Markowitz, J. S., Weissman, M. M., Oullette, R., Lish, J. D., & Klerman, G. L. (1989). Quality of life in panic disorder. Archives of General Psychiatry, 46, 984–992.PubMed

Masand, P. S., & Gupta, S. (2003). The safety of SSRIs in generalized anxiety disorder: any reason to be anxious? Expert Opinion in Drug Safety, 2, 485–493.CrossRef

Massion, A. O., Warshaw, M. G., & Keller, M. B. (1993). Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. American Journal of Psychiatry, 150, 600–607.PubMed

McCurry, S. M., Gibbons, L. E., Logsdon, R. G., & Teri, L. (2004). Anxiety and nighttime behavioral disturbances: awakenings in patients with Alzheimer's disease. Journal of Gerontological Nursing, 30, 12–20.PubMed

McIntyre, R. S., & O'Donovan, C. (2004). The human cost of not achieving full remission in depression. Canadian Journal of Psychiatry, 49(Suppl. 1), 10s–16s.

Melartin, T. K., Rytsala, H. J., Leskela, U. S., Lestela-Mielonen, P. S., Sokero, T. P., & Isometsa, E. T. (2002). Current co-morbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. Journal of Clinical Psychiatry, 63, 126–134.PubMed

Mikkelsen, R. L., Middelboe, T., Pisinger, C., & Stage, K. B. (2004). Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD): a review. Nordic Journal of Psychiatry, 58, 65–70.PubMedCrossRef

Mittermaier, C., Dejaco, C., Waldhoer, T., Oefferlbauer-Ernst, A., Michsler, W., Beier, M., et al. (2004). Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosomatic Medicine, 66, 79–84.PubMedCrossRef

Noorbala, A. A., Bagheri, Yadzi, S. A., Yasamy, M. T., & Mohammad, K. (2004). Mental health survey of the adult population in Iran. British Journal of Psychiatry, 184, 70–73.PubMedCrossRef

O'Donovan, C. (2004). Achieving and sustaining remission in depression and anxiety disorders: introduction. Canadian Journal of Psychiatry, 49(Suppl.1), 5s–9s.

Ohaeri, J. U. (1992) Experiences of isolated sleep paralysis in clinical practice in Nigeria. Journal of National Medical Association, 84, 521–523.

Ohaeri, J. U. (1993) Interpreting the dreams of Nigerian psychiatric patients. Nigerian Medical Journal, 24, 65–68.

Ohaeri, J. U. (1997) Experience of cognitive behaviour therapy in psychiatric practice in Nigeria. II. Illustrative case histories. African Journal of Medicine and Medical Sciences, 26, 197–201.PubMed

Ohaeri, J. U. (1998–1999) Experience of dreams with manifest content of food (Food dreams) among 431 Nigerians. Psychopathologie Africaine, 29(1):23–39.CrossRef

Ohaeri, J. U., & Sunmola, A. M. (1994) The pattern of dreams of a sample of Nigerians. Journal of Analytical Psychology, 39, 361–372.PubMedCrossRef

Olusina, A. K., & Ohaeri, J. U. (2003). Subjective quality of life of recently discharged Nigerian psychiatric patients. Social Psychiatry and Psychiatric Epidemiology, 38, 707–714.PubMedCrossRef

Pampallona, S., Bollini, P., Tibaldi, G., Kupelnick, B., & Munizza, C. (2004). Combined pharmacotherapy and psychological treatment for depression: a systematic review. Archives of General Psychiatry, 61, 714–719.PubMedCrossRef

Parker, G., Hadzi-Pavlovic, D., Roussos, J., Wilhelm K., Mitchell P., Austin M. P., et al. (1998). Non-melancholic depression: the contribution of personality, anxiety and life events to sub-classification. Psychological Medicine, 28, 1209–1219.PubMedCrossRef

Pollack, M. H., & Marzol, P. C. (2000). Panic: course, complications and treatment of panic disorder. Journal of Psychopharmacology, 14(2 Suppl 1), S25–S30.PubMed

Rickels, K., & Rynn, M. (2002). Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry, 63(Suppl. 14), 9–16.PubMed

Ritchie, K., Artero, S., Beluche, I., Ancelin, M. L., Mann, A., Dupuy, A. M., et al. (2004). Prevalence of DSM-IV psychiatric disorders in the French elderly population. British Journal of Psychiatry, 184, 147–152.PubMedCrossRef

Royal Australia and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia. (2003). Australia and New Zealand clinical practice guidelines for treatment of panic disorder and agoraphobia. Australia and New Zealand Journal of Psychiatry, 37, 641–656.CrossRef

Royal Australia and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression. (2004). Australia and New Zealand clinical practice guidelines for treatment of depression. Australia and New Zealand Journal of Psychiatry, 38, 389–407.CrossRef

Segal, Z. W., Whitney, D. K., Lam, R. W., & CANMAT Depression Work Group. (2001). Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy. Canadian Journal of Psychiatry, 46(Suppl. 1), 29s–37s.

Snyderman, S. H., Rynn, M. A., Bellew, K., & Rickels, K. (2004). Paroxetine in the treatment of generalized anxiety disorder. Expert Opinion in Pharmacotherapy, 5, 1799–1806.CrossRef

Stein, D. J. (2004). Algorithms for primary care: an evidence based approach to the pharmacotherapy of depression and anxiety disorders. Primary Psychiatry, 11, 55–78.

Stein, D. J., Berk, M., Els, C., Emsley, R. A., Gittelson, L., Wilson, D., et al. (1999). A double-blind placebo-controlled trial of paroxetine in the management of social phobia in South Africa. South Africa Medical Journal, 89, 402–406.

Stein, D. J., Stein, M. B., Pitts, C. D., Kumar, R., & Hunter, B. (2002a). Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. Journal of Clinical Psychiatry, 63, 152–155.PubMed

Stein, D. J., Versiani, M., Hair, T., & Kumar, R. (2002b). Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Archives of General Psychiatry, 59, 1111–1118.PubMedCrossRef

Tausig, M., Subedi, S., Broughton, C. L., Subedi, J., & Williams-Blangero, S. (2003). Measuring community mental health in developing societies: evaluation of a checklist format in Nepal. International Journal of Social Psychiatry, 49, 269–286.PubMedCrossRef

Tsao, J. C., Dobalian, A., Moreau, C., & Dobalian, K. (2004). Stability of anxiety and depression in a national sample of adults with human immunodeficiency virus. Journal of Nervous and Mental Disorders, 192, 111–118.CrossRef

Tyrer, P. (2001). The case for cothymia: mixed anxiety and depression as a single diagnosis. British Journal of Psychiatry, 179, 191–193.PubMedCrossRef

Tyrer, P., Seivewright, H., Simmonds, S., & Johnson, T. (2001). Prospective studies of cothymia (mixed anxiety depression): how do they inform clinical practice? European Archives of Psychiatry and Neuroscience, 251(Suppl 2), II53–II56.

Udofia, O. (2005). SSRI/TCA sequential therapy: a cost effective drug regime for the long term management of depression. Nigerian Journal of Medicine, 3(2), 33–37.

van Ameringen, M., Allgulander, C., Bandelow, B., Griest, J. H., Hollander, E., Montgomery, S. A., et al. (2003). WCA recommendations for the long-term treatment of social phobia. CNS Spectrum, 8(8 Suppl. 1), 40–52.

van den Heuvel, O. A., van de Wetering, B. J., Veltman, D. J., & Pauls, D. L. (2000). Genetic studies of panic disorder: a review. Journal of Clinical Psychiatry, 61, 756–766.PubMed

Wagstaff, A. J., Cheer, S. M., Matheson, A. J., Ormrod, D., & Goa, K. L. (2002). Spotlight on paroxetine in psychiatric disorders in adults. CNS Drugs, 16, 425–434.PubMedCrossRef

Young, E. A., Abelson, J. l. L., & Cameron, O. G. (2004). Effect of co-morbid anxiety disorders on the hypothalamic pituitary axis response to a social stressor in major depression. Biological Psychiatry, 56, 113–120.PubMedCrossRef

Zimmerman, M., Chelminski, I., & McDermut, W. (2002). Major depressive disorder and axis 1 diagnostic co-morbidity. Journal of Clinical Psychiatry, 63, 187–193.PubMed

Zohar, J., & Westenberg, H. G. (2001). Anxiety disorders: a review of tricyclic antidepressants and selective serotonin re-uptake inhibitors. Acta Psychiatrica Scandinavica, 403(Suppl), 39–49.

Title: The Management of Anxiety and Depressive Disorders: A Review
Author: Jude U. Ohaeri
Publication date: 01-04-2006
Publisher: Springer-Verlag
Published in: International Journal of Mental Health and Addiction / Issue 2/2006
Print ISSN: 1557-1874
Electronic ISSN: 1557-1882
DOI: https://doi.org/10.1007/s11469-006-9016-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Management of Anxiety and Depressive Disorders: A Review

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2006

Reflective Activity and its Measurement

The Psychology of the Fruit Machine: The Role of Structural Characteristics (Revisited)

Critical Commentary by an EGM Gambler, October 2004: Introduction by Jennifer Borrell

A Step Towards Academic Inclusiveness

Gambling Problems in Youth

The Stigmatization of Neurological and Mental Health Conditions: Epilepsy as a Case Example